国药股份(600511) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 12,122,142,562.33, representing a year-on-year increase of 7.98%[4] - The net profit attributable to shareholders for Q1 2024 was CNY 459,454,518.02, reflecting a growth of 10.86% compared to the same period last year[4] - The basic earnings per share for Q1 2024 was CNY 0.6089, which is an increase of 10.86% year-on-year[5] - The net profit for Q1 2024 was CNY 495,118,467.38, which is an increase of 9.9% from CNY 450,409,271.64 in Q1 2023[19] - The profit attributable to shareholders of the parent company for Q1 2024 was CNY 459,454,518.02, compared to CNY 414,409,175.82 in Q1 2023, reflecting a growth of 10.9%[19] - The total comprehensive income for Q1 2024 was ¥309,812,727.18, compared to ¥283,206,166.14 in Q1 2023, indicating an increase of 9.4%[25] Cash Flow - The net cash flow from operating activities for Q1 2024 was negative at CNY -1,719,799,376.67, indicating a significant cash outflow[4] - The cash inflow from operating activities totaled ¥5,539,406,936.00 in Q1 2024, compared to ¥5,368,466,798.45 in Q1 2023, showing a growth of 3.2%[26] - The cash flow from operating activities showed a net outflow of ¥301,387,089.18 in Q1 2024, compared to a net inflow of ¥78,555,396.09 in Q1 2023[26] - The net cash outflow from operating activities was ¥1.72 billion in Q1 2024, compared to a net outflow of ¥1.14 billion in Q1 2023, indicating a worsening cash flow situation[20] - The cash inflow from investment activities was ¥18.65 million in Q1 2024, significantly higher than ¥5.85 million in Q1 2023, showing a substantial increase in investment returns[21] - The net cash outflow from investment activities was ¥2.33 million in Q1 2024, an improvement from a net outflow of ¥15.82 million in Q1 2023, reflecting better investment management[21] - The cash inflow from financing activities totaled ¥338.20 million in Q1 2024, slightly lower than ¥372.03 million in Q1 2023, indicating a decrease in financing activities[21] - The net cash outflow from financing activities was ¥116.58 million in Q1 2024, compared to a net outflow of ¥161.78 million in Q1 2023, showing improved cash management in financing[21] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to CNY 32,919,056,402.95, a slight increase of 1.44% from the end of the previous year[5] - The total liabilities as of the reporting date were CNY 14,898,012,994.93, slightly down from CNY 14,919,938,717.90 in the previous year[16] - The total assets as of the reporting date were CNY 32,919,056,402.95, compared to CNY 32,453,092,592.42 in the previous year, showing an increase of 1.4%[16] - The total current assets were approximately ¥16.99 billion as of March 31, 2024, down from ¥18.17 billion at the end of 2023, reflecting a decline in liquidity[22] - The total liabilities decreased to ¥10,155,730,572.50 in Q1 2024 from ¥11,571,806,815.96 in Q1 2023, a reduction of approximately 12.2%[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,921[8] - The largest shareholder, China National Pharmaceutical Group Co., Ltd., held 54.72% of the shares, totaling 412,841,745 shares[8] - The company reported a total of 211,685,171 shares held by its largest shareholder, China National Pharmaceutical Group, indicating significant ownership concentration[9] Research and Development - Research and development expenses for Q1 2024 were CNY 13,941,626.51, down from CNY 16,684,728.20 in Q1 2023, indicating a decrease of 16.4%[18] - The company's research and development expenses were not specified in the report, indicating a potential area for future disclosure[24] Other Financial Metrics - The company reported non-recurring gains of CNY 1,472,368.63 for the period, after accounting for tax and minority interests[7] - The weighted average return on equity for Q1 2024 was 2.87%[5] - The company reported an investment income of CNY 104,978,672.01 for Q1 2024, up from CNY 80,674,195.75 in Q1 2023, representing a growth of 30.0%[18] - The company's contract liabilities increased significantly to ¥69,816,037.03 in Q1 2024 from ¥8,228,053.18 in Q1 2023, marking a substantial rise of 749.5%[23] Miscellaneous - The report was issued by the board of directors of China National Pharmaceutical Group Corporation on April 25, 2024[29] - The company did not execute any adjustments related to new accounting standards for the first quarter of 2024[29]